WMT

103.77

-1.23%↓

PG

157.68

-1.79%↓

KO

66.52

-0.66%↓

PM

162.34

-2.73%↓

PEP

141.12

+0.15%↑

WMT

103.77

-1.23%↓

PG

157.68

-1.79%↓

KO

66.52

-0.66%↓

PM

162.34

-2.73%↓

PEP

141.12

+0.15%↑

WMT

103.77

-1.23%↓

PG

157.68

-1.79%↓

KO

66.52

-0.66%↓

PM

162.34

-2.73%↓

PEP

141.12

+0.15%↑

WMT

103.77

-1.23%↓

PG

157.68

-1.79%↓

KO

66.52

-0.66%↓

PM

162.34

-2.73%↓

PEP

141.12

+0.15%↑

WMT

103.77

-1.23%↓

PG

157.68

-1.79%↓

KO

66.52

-0.66%↓

PM

162.34

-2.73%↓

PEP

141.12

+0.15%↑

Search

Lifecore Biomedical Inc

Atvērts

SektorsPatēriņa aizsardzības

7.83 0.38

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

7.63

Max

7.93

Galvenie mērījumi

By Trading Economics

Ienākumi

14M

-1.1M

Pārdošana

1.3M

36M

EPS

-0.253

Peļņas marža

-3.147

Darbinieki

406

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+11.32% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 3. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

9.8M

236M

Iepriekšējā atvēršanas cena

7.45

Iepriekšējā slēgšanas cena

7.83

Ziņu noskaņojums

By Acuity

15%

85%

5 / 150 Rangs Consumer defensive

Lifecore Biomedical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 17. sept. 23:01 UTC

Iegādes, apvienošanās, pārņemšana

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

2025. g. 17. sept. 22:48 UTC

Iegādes, apvienošanās, pārņemšana

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

2025. g. 17. sept. 21:59 UTC

Peļņas

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

2025. g. 17. sept. 23:44 UTC

Tirgus saruna

Nikkei May Rise as Yen Weakens -- Market Talk

2025. g. 17. sept. 23:39 UTC

Tirgus saruna

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

2025. g. 17. sept. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

2025. g. 17. sept. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

2025. g. 17. sept. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

2025. g. 17. sept. 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

2025. g. 17. sept. 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

2025. g. 17. sept. 21:00 UTC

Peļņas

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

2025. g. 17. sept. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 17. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 17. sept. 19:59 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. sept. 19:59 UTC

Tirgus saruna

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

2025. g. 17. sept. 19:07 UTC

Tirgus saruna

Oil Futures Snap Three-Session Winning Streak -- Market Talk

2025. g. 17. sept. 18:43 UTC

Tirgus saruna

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

2025. g. 17. sept. 18:38 UTC

Tirgus saruna

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

2025. g. 17. sept. 18:20 UTC

Tirgus saruna

Gold Dips After Quarter-Point Rate Cut -- Market Talk

2025. g. 17. sept. 18:18 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. sept. 18:18 UTC

Tirgus saruna

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

2025. g. 17. sept. 18:14 UTC

Tirgus saruna

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

2025. g. 17. sept. 17:59 UTC

Tirgus saruna

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

2025. g. 17. sept. 17:15 UTC

Iegādes, apvienošanās, pārņemšana

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

2025. g. 17. sept. 17:06 UTC

Iegādes, apvienošanās, pārņemšana

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

2025. g. 17. sept. 16:51 UTC

Peļņas

Correct: Exor 1H Net Loss -EUR624M

2025. g. 17. sept. 16:34 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. sept. 16:34 UTC

Tirgus saruna

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

2025. g. 17. sept. 16:25 UTC

Peļņas

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

2025. g. 17. sept. 16:23 UTC

Peļņas

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Salīdzinājums

Cenas izmaiņa

Lifecore Biomedical Inc Prognoze

Cenas mērķis

By TipRanks

11.32% augšup

Prognoze 12 mēnešiem

Vidējais 8.75 USD  11.32%

Augstākais 10 USD

Zemākais 7.5 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Lifecore Biomedical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

5 / 150 Rangs Patēriņa aizsardzības

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
help-icon Live chat